Last reviewed · How we verify
NCT07197996: RETRAIN 2
The RETRAIN Trial Phase 2
NA trial testing Intermittent Pneumatic Compression in Ischaemic Stroke in 80 participants. Currently enrolling.
1 March 2026
Quick facts
| Lead sponsor | Firstkind Ltd |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 July 2025 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Intermittent Pneumatic Compression
- geko® T3
Conditions studied
- Ischaemic Stroke — all drugs for Ischaemic Stroke →
Sponsor
Firstkind Ltd
Who can join
18 and older, any sex, with Ischaemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom. This single-center prospective randomised study aims to measure cerebral blood flow and oxygen delivery in patients who have recently suffered an ischaemic stroke and are using either the geko® neuromuscular electrostimulation device or an intermittent pneumatic compression (IPC) device as part of their routine clinical care. The geko® device stimulates a nerve in the lower leg, inducing muscle contractions that enhance blood circulation. The IPC device applies controlled external pressure through compressed air and a pump, cyclically inflating and deflating chambers in a sleeve worn on the leg. This mimics the action of calf muscles to promote blood flow. The primary objective of this study is to assess the effect of the geko® and IPC devices on cerebral blood flow in stroke patients, specifically during the hyperacute phase (within 36 hours) following an ischaemic stroke. Both devices will be used as part of standard care for VTE prevention. Cerebral blood flow will be measured using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07197996
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intermittent Pneumatic Compression
Trials testing the same drug.
- NCT03856281 — Intermittent Pneumatic Compression for Treating Lower Limb Lymphoedema · NA · completed
- NCT03806322 — A Better Way to Decrease Knee Swelling in Patients With Knee Osteoarthritis · NA · completed
Other recruiting trials for Ischaemic Stroke
Currently open trials in the same condition.
- NCT06987643 — A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke · Phase 2 · recruiting
- NCT06940635 — Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stro · NA · recruiting
- NCT05922540 — a Cohort Study of Ischemic Cerebrovascular Disease · recruiting
Other Firstkind Ltd trials
Trials by the same sponsor.
- NCT05476913 — GEKO Venous Thromboembolism Prevention Study · NA · recruiting
- NCT04927234 — Foot and Ankle Post-operative Oedema Management Using Geko™ · NA · completed
- NCT05057793 — Efficacy Study for Geko Device in VLU Patients (Canada) · NA · terminated
- NCT04309110 — Efficacy of Adhesive Strength of New Hydrogel Formulation · NA · completed
- NCT04700735 — Cross Therapy Registry - Edema - US · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07197996 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Firstkind Ltd
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07197996.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing